FindTrial
Sign In

Development of clinically high efficient platforms for individualised treatment of cervix cancer

Developing clinical high efficiency platforms for individualised treatment through integration of advanced radiation technology, quantitative imaging and molecular biology and machine learning for treatment of cervix cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035810
Enrollment
1800
Registered
2021-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

None listed

Sponsors

Science and Engineering Research Board SERB
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy. 2. Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.

Exclusion criteria

Exclusion criteria: 1. Lack of disease or toxicity outcomes. 2. Lack of images in the hospital database.

Design outcomes

Primary

MeasureTime frame
a) Generation of software for automated target delineation for cervix cancer. b) Development and validation of Normal Tissue Complication Plots. c) Identify â??high risk patient populationâ?? that may benefit from intensification of treatment in future.Timepoint: 3 Years—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Supriya Chopra Sastri

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

supriyasastri@gmail.com9930958309

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026